glp·helper
glphelper.com/tirzepatide/florida/sarasota
Dual GIP / GLP-1 receptor agonistFDA-approved May 2022 (Mounjaro) · November 2023 (Zepbound)Rx · Subcutaneous injection · Once weekly

Tirzepatide® providers &
prescriptions in Sarasota, FL

Verified Tirzepatide providers in Sarasota, FL. Checked against the NPI registry, sorted by waitlist, not by who pays us.[7]

city providers
37
as of today
median wait
8d
first visit
telehealth
71%
of providers
cash range
$25 to $1,150
monthly
§ 02Provider directory: Florida
38 of 38 shown

Find a Tirzepatide provider in Florida.

Every entry is checked against the NPI registry and the Florida medical board. Listings are ordered by current waitlist. The provider who can see you fastest appears first. We do not accept payment for placement.

Filter →
Type
Provider
City
Waitlist
Insurance
Browse by Florida city · /tirzepatide/florida/{city}
§ 03Getting Tirzepatide in Sarasota
38 providers · Sarasota, FL

How to get Tirzepatide in Sarasota.

38 GLP-1 prescribers and 7 local resource types are on record for Sarasota, plus 3 nearby towns in the directory.

Prescribers in Sarasota
38 prescribers
38 GLP-1 prescribers in Sarasota, most listed as Internal Medicine, Endocrinology, Diabetes & Metabolism (15), Family Medicine (13) and Internal Medicine (8). Any Florida-licensed physician, nurse practitioner, or PA can prescribe Tirzepatide, over video or in person. The nearest towns on record are Bradenton (29 providers), North Port (28 providers) and St Petersburg (29 providers).
Around the prescription in Sarasota
7 listed nearby
38 dietitians, 9 nutritionists, 6 gyms, 6 fitness clubs, 6 trainers, 6 physiotherapists and 6 places to move are on record near Sarasota.
Medicaid (weight loss)
Diabetes only
As of April 2026, Florida Medicaid covers GLP-1s for diabetes but not for weight loss. Employer and private plans can still cover them; that is a plan-design choice, not a state rule.

Medicaid status above is for weight-loss use and was compiled April 2026 from KFF and public Medicaid trackers; only 13 states cover it and several are mid-change, so confirm Florida’s current Medicaid and plan rules before booking. GLPHelper provides information and provider matching, not medical or coverage advice.

§ 04Medication factsheet
cited · last review 2026.05.19

The molecule in Mounjaro and Zepbound. It acts on two gut-hormone pathways, GIP and GLP-1.

Tirzepatide is a once-weekly injection sold by Eli Lilly as Mounjaro (for type 2 diabetes) and Zepbound (for chronic weight management). It is the first approved dual GIP/GLP-1 receptor agonist. It activates two gut-hormone pathways rather than one, which is associated with greater average weight loss than single GLP-1 agonists.[2][3]

In SURMOUNT-1, adults with obesity (without diabetes) lost a mean of 20.9% of body weight on the 15 mg dose at 72 weeks, versus 3.1% on placebo. In the SURPASS-2 head-to-head diabetes trial, tirzepatide produced larger HbA1c and weight reductions than semaglutide 1 mg.[1]

At a glanceMultiple (brand-specific)
Generic name
tirzepatide
Drug class
Dual GIP / GLP-1 receptor agonist
Manufacturer
Eli Lilly
FDA approved
May 2022 (Mounjaro) · November 2023 (Zepbound)
Approved use
Type 2 diabetes (Mounjaro) · chronic weight management (Zepbound)
Off-label use
Use outside the approved brand/indication is off-label
Administration
Subcutaneous injection · Once weekly
Available doses
2.5 mg · 5 mg · 7.5 mg · 10 mg · 12.5 mg · 15 mg
Half-life
≈ 5 days
Pregnancy
Discontinue ≥ 2 months before a planned pregnancy; may reduce oral contraceptive efficacy

Community health · CDC

Weight & metabolic health in Sarasota

Sarasota, Florida has a population of 54,842 people. The adult obesity rate in Sarasota is an age-adjusted estimate of 32.9%, 3.3 percentage points above the Florida state rate of 29.6%. Diagnosed diabetes reaches 9.8% of adults in Sarasota. Inactivity, meaning no leisure-time physical activity reported in the past month, affects 23.8% of adults in Sarasota.

of Sarasota adults have obesity
32.9%
diagnosed diabetes
9.8%
no regular physical activity
23.8%

Age-adjusted estimates for Sarasota, community figures, not individual risk. CDC PLACES, 2025 release.

Estimate your weight losswhat to expect week by week
§ 05Support around Tirzepatide in Sarasota
6 nutritionists

The prescription is one part. Here is the rest, in Sarasota.

Trials of tirzepatide paired the drug with diet counseling and regular activity. Every name below is a real listing near Sarasota, FL, ordered as the registry lists them, never by who pays us.

Nutritionists

A nutritionist helps you get enough protein and fiber while the medication cuts your appetite. Call to ask what they cover.

Shannon Barnhouse, CLC
NUTRITIONIST
Nutritionist
2062 Pinehurst St
Call 304-412-6826NPI 1548655756
Julie Calmes, DN
NUTRITIONIST
Nutritionist
11505 Palmbrush Trl Ste 220
Call 941-315-6182NPI 1881020279
Nora Clemens, ND
NUTRITIONIST
Nutritionist
11505 Palmbrush Trl
Call 941-315-6182NPI 1912311895
Paul Leonard
NUTRITIONIST
Nutritionist
5606 Beneva Woods Cir
Call 412-944-6968NPI 1467224451
Bethany Reul
NUTRITIONIST
Nutritionist · Education
5899 Whitfield Ave Ste 207
Call 502-594-0239NPI 1437679974
Ryan Stoner, FDN-P
NUTRITIONIST
Nutritionist · Education
5911 N Honore Ave Ste 103
Call 941-444-1441NPI 1407669914

Gyms near you

A gym gives you the regular movement that keeps muscle while the weight comes off.

EōS Fitness
GYM
4.3 on Google · 1486 reviews
4940 S Tamiami Trl
Website
Crunch Fitness - Sarasota University
GYM
4.3 on Google · 1227 reviews
8440 N Lockwood Ridge Rd
Website
Crunch Fitness - East Sarasota
GYM
4.3 on Google · 1020 reviews
3762 Bee Ridge Rd
Website
Planet Fitness
GYM
4.2 on Google · 888 reviews
501 N Beneva Rd
Website
Amped Fitness (Sarasota)
GYM
4.1 on Google · 740 reviews
935 N Beneva Rd Ste 501
Website
Anytime Fitness
GYM
4.7 on Google · 452 reviews
8309 N Lockwood Ridge Rd
Website
§ 06Clinical evidence
STEP 1 to 4 + SELECT (N = 17,604)

What the trials actually showed.

We summarize the SURMOUNT weight-management program and the SURPASS diabetes program, including the SURPASS-2 head-to-head against semaglutide. Figures are means at each trial's primary endpoint.

SURMOUNT-1 randomized 2,539 adults with obesity (without diabetes) across 72 weeks. Mean weight change was −15.0% (5 mg), −19.5% (10 mg), and −20.9% (15 mg) versus −3.1% with placebo. A majority of patients on the higher doses lost ≥20% of body weight.[2]
STEP / SELECT endpoint table2.4 mg / 68 wk
Mean weight change (15 mg)
−20.9%
SURMOUNT-1, 72 wk vs −3.1% placebo[2]
Mean weight change (5 mg)
−15.0%
SURMOUNT-1, 72 wk[2]
HbA1c reduction (T2D)
−1.8 to −2.6%
SURPASS program[4]
vs. semaglutide 1 mg
Superior
SURPASS-2, HbA1c + weight[3]
Effect size varies with baseline characteristics and adherence. Individual response may differ materially.
average tirzepatide weight loss →mapped to your starting weight
§ 07Safety & adverse events
from FDA label, sect. 6.1

Most side effects are gastrointestinal and resolve within weeks.

The most common adverse events in STEP trials were nausea (44%), diarrhea (30%), and vomiting (24%), more frequent at the 2.4 mg dose than at Ozempic doses, but typically transient.[1] Serious events were rare but include pancreatitis, gallbladder disease, and an FDA boxed warning regarding thyroid C-cell tumors based on rodent data.[8]

Boxed warning. Boxed warning: risk of thyroid C-cell tumors. Contraindicated in patients with a personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN-2).
Effect
Frequency
Severity
Note
Nausea
12 to 24%
mild
Dose-dependent; usually eases after titration
Diarrhea
12 to 19%
mild
More frequent during dose escalation
Vomiting
5 to 13%
mild
Reduced by slower titration
Constipation
6 to 17%
mild
Decreased appetite
5 to 11%
mild
Expected pharmacologic effect
Pancreatitis
<0.3%
serious
Discontinue if acute pancreatitis is suspected
Gallbladder disease
~1 to 2%
serious
Cholelithiasis risk rises with rapid weight loss
Thyroid C-cell tumors
rodent data
boxed warning
Contraindicated with MTC or MEN-2 history
§ 08Cost & coverage, published, not gated
USD · monthly

Most directories hide the price. We don't.

Cash prices vary roughly 50× between the brand-name retail rate and a manufacturer savings card. The number you actually pay depends on your insurance plan, your diagnosis code, and which pharmacy fills the script. Here are the ranges, plainly.

Data sources: GoodRx national retail survey[6], CMS Part D formulary files[5], Novo Nordisk patient access program.

Cash, Zepbound (no insurance)
$1,000 to $1,300
per month
Brand-name retail; Lilly self-pay vials lower for some doses[6]
Cash, Mounjaro (no insurance)
$1,000 to $1,200
per month
Brand-name retail average[6]
Commercial insurance (T2D)
$25 to $250
per month copay
Usually covered for diabetes with prior authorization
Commercial insurance (weight)
Often denied
Zepbound is on-label but frequently requires PA
Medicare Part D
$0 to $100
per month
T2D covered; weight-loss indication not covered by law[5]
Manufacturer savings card
as low as $25
per month
Commercial insurance only; eligibility limits apply
Updated weekly · last fetch 2026-05-18 04:00 UTCCost methodology →
Find Tirzepatide providers in Florida

NPI-verified Tirzepatide (tirzepatide) prescribers and clinics, ordered by availability, never by who pays us.

Tirzepatide in other states

Find NPI-verified Tirzepatide (tirzepatide) doctors, clinics, and pharmacies in the states we cover, ordered by availability, never by who pays us.

Related GLP-1 research
§ 09Frequently asked: Tirzepatide in Florida

The questions people ask before they book.

Answers reviewed by the GLPHelper Medical Team. Citations link to primary sources, never marketing copy.

Yes. Tirzepatide is the active molecule in both Eli Lilly products. Mounjaro is approved for type 2 diabetes; Zepbound is approved for chronic weight management. They are the same drug with different approved indications, and insurers treat them as separate products.[1]